目的 探讨根据细菌β-内酰胺酶（BLs）选用β-内酰胺/β-内酰胺酶抑制剂（BL/BLI）对细菌性重症肺炎抗生素相关性腹泻（AAD）发生率的影响。方法 回顾性分析细菌性重症肺炎患儿临床资料，将未行BLs 检测、经验性选用阿莫西林/克拉维酸的248 例患儿及根据BLs 选用阿莫西林或阿莫西林/克拉维酸的323 例患儿作为阿莫西林组；将未检测BLs 直接选用哌拉西林/他唑巴坦的208 例患儿与根据BLs 选用哌拉西林或哌拉西林/他唑巴坦的291 例患儿作为哌拉西林组；将未检测BLs 而直接选用头孢哌酮/舒巴坦的191 例患儿及根据BLs 选用头孢哌酮或头孢哌酮/舒巴坦的341 例患儿作为头孢哌酮组，监测各组患儿的AAD 发生率，分析是否根据BLs 选用BL/BLI 的重症肺炎患儿AAD 发生率和临床症状差异。结果 各组未检测 BLs 直接选用BL/BLI 患儿的AAD 发生率均高于根据BLs 选用BL（BLs 阴性）或BL/BLI（BLs 阳性）患儿的AAD 发生率，P < 0.01。根据BLs 选用BL/BLI 患儿的AAD 病程、抗生素使用时间和住院日均短于未检测BLs 患儿者（P < 0.01）。结论 根据BLs 选用BL/BLI 对降低细菌性重症肺炎患儿AAD 发生率和减轻症状有重要作用。
Abstract
Objective To study the effect of β-lactamase (BLs) detection and β-lactam/β-lactamase inhibitor (BL/BLI) on the incidence of antibiotic-associated diarrhea (AAD) in children with severe bacterial pneumonia. Methods The clinical data of the children with bacterial severe pneumonia were retrospectively studied. Of all the patients, 248 using amoxicillin/clavulanate but without BLs detection and 323 using amoxicillin (BLs negative) or amoxicillin/clavulanate (BLs positive) were used as the amoxicillin group; 208 patients using piperacillin/tazobactam but without BLs detection and 291 patients using piperacillin (BLs negative) or piperacillin/tazobactam (BLs positive) were used as the piperacillin group; and 191 patients using cefoperazone/sulbactam but without BLs detection and 341 patients using cefoperazone (BLs negative) or cefoperazone/sulbactam (BLs positive) were used as the cefoperazone group. The incidence and clinical symptoms of AAD between the undetected and detected BLs patients were compared. Results The incidences of AAD in the amoxicillin, piperacillin and cefoperazone groups without BLs detection groups were significantly higher than those in the corresponding groups with negative or positive results of BLs detection (P < 0.01). The durations of diarrhea, antibiotic use and hospitalization stay in AAD patients receiving BLs detection were shorter than in those without receiving BLs detection (P < 0.01). Conclusions It is very important to detect BLs for reducing the incidence and relieving symptoms of AAD in children with severe bacterial pneumonia.
关键词
细菌性重症肺炎 /
抗生素相关性腹泻 /
β-内酰胺酶 /
β-内酰胺/β-内酰胺酶抑制剂 /
儿童
Key words
Severe bacterial pneumonia /
Antibiotic-associated diarrhea /
β-lactamase /
β-lactam/β-lactamase inhibitor /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 李自华, 程国平, 汪在华, 等. 细菌性重症肺炎患儿抗生素 相关性腹泻发病率及高危因素分析[J]. 临床儿科杂志, 2015, 33(8): 698-701.
[2] 中华医学会儿科学分会呼吸学组,《中华儿科杂志》编辑委 员会. 儿童社区获得性肺炎管理指南(2013 修订)( 上)[J]. 中 华儿科杂志, 2013, 51(10): 745-752.
[3] 洪香华,孙自镛. 临床微生物与寄生虫病[M]//尚红, 王毓三, 申子瑜. 全国临床检验操作规程. 第4 版. 北京: 人民卫生 出版社, 2015: 574-625.
[4] Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twenty-fifth informational supplement[M]. M100S25. Wayne, PA: CLSI, 2015: 108-110.
[5] 中华人民共和国卫生部. 医院感染诊断标准( 试行) [J]. 中华 医学杂志, 2001, 81(5): 314-320.
[6] Luzina EV, Lareva NV. Antibiotic-associated diarrhea in clinical practice[J]. Ter Arkh, 2013, 85(2): 85-88.
[7] 鲍连生, 张振, 张多. 重症细菌性肺炎患儿继发抗生素相关 性腹泻临床分析 [J]. 临床儿科杂志, 2014, 32(6): 562-563.
[8] 周华, 李光辉, 陈佰义, 等. 中国产超广谱β-内酰胺酶肠杆 菌科细菌感染应对策略专家共识[J]. 中华医学杂志, 2014, 94(24): 1847-1856.
[9] Rashid MU, Rosenborg S, Panagiotidis G, et al. Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota[J]. Int J Antimicrob Agents, 2015, 46(1): 60-65.
[10] Dubreuil L, Odou MF. Anaerobic bacteria and antibiotics: What kind of unexpected resistance could I find in my laboratory tomorrow[J]. Anaerobe, 2010, 16(6): 555-559.
[11] Charteris WP, Kelly PM, Morelli L, et al. Antibiotic susceptibility of potentially probiotic Lactobacillus species[J]. J Food Prot, 1998, 61(12): 1636-1643.
[12] Masco L, Van Hoorde K, De Brandt E, et al. Antimicrobial susceptibility of Bifidobacterium strains from humans, animals and probiotic products[J]. J Antimicrob Chemother, 2006, 58(1): 85-94.
[13] Bergogne-Bérézin E. Treatment and prevention of antibiotic associated diarrhea[J]. Intern J Antimicrob Agent, 2000, 16(4): 521-526.
[14] Toussaint KA, Gallagher JC. β-Lactam/β-Lactamase inhibitor combinations: from then to now[J]. Ann Pharmacother, 2015, 49(1): 86-98.
基金
湖北省卫生计生委科研项目（WJ2015WB248）。
PDF(1356 KB)
